Study summary

Hormone blockade shrank androgen-receptor-positive salivary cancers when two drugs were combined

DISCOVARY trial (darolutamide) · 57 people, phase 2 · Published September 2026, Journal of Clinical Oncology

45.2%response rate with darolutamide plus goserelin

What was tested

Darolutamide, a prostate cancer pill that blocks the androgen receptor, alone or with goserelin (which lowers testosterone), for androgen-receptor-positive salivary gland carcinoma.

What they found

What it means

A chemotherapy-free option for salivary duct carcinoma, which is often androgen-receptor-positive.

J Clin Oncol, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.